This website contains promotional content and is intended for Healthcare Professionals

Discover clinical outcomes with iGlarLixi versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial leading to advancing therapy in sub-optimally controlled basal insulin-treated Type-2 diabetes.

MAT-BH-2300623/v1/November2023